Technology

Catalent commits to ADCs by upping its stake in Redwood

News from Interphex 2014

Catalent commits to ADCs by upping its stake in Redwood

By Dan Stanton

Catalent has increased its stake in Redwood Biosciences telling us it is committed to the development of antibody-drug conjugates (ADCs) and the SMARTag technology platform.